文献速递肿瘤 PET/CT

原发性前列腺癌患者中[68Ga]Ga-P16-093与[68Ga]Ga-PSMA-11 PET/CT的前瞻性头对头比较

A prospective head-to-head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-05-26

50例未经治疗、经穿刺活检组织学确诊的原发性前列腺癌患者在一周内先后接受[68Ga]Ga-P16-093与[68Ga]Ga-PSMA-11 PET/CT。前者检出更多阳性肿瘤(202 vs 190,P=0.002),尤其在低危和中危患者的前列腺内病灶(21/23 vs 15/23,P=0.031),大多数匹配肿瘤的SUVmax更高(13.7±10.2 vs 11.4±8.3,P<0.001)。作者认为[68Ga]Ga-P16-093可能作为前列腺癌检测的替代显像剂。

要点

  • [68Ga]Ga-P16-093 PET/CT检出阳性肿瘤202个,[68Ga]Ga-PSMA-11 PET/CT检出190个(P=0.002)。
  • 低危和中危患者前列腺内病灶检出:[68Ga]Ga-P16-093为21/23,[68Ga]Ga-PSMA-11为15/23(P=0.031)。
  • 正常器官分布不同:前者肾脏和膀胱摄取更低,腮腺、肝脏和脾脏摄取更高。

核心结论

  • [68Ga]Ga-P16-093 PET/CT较[68Ga]Ga-PSMA-11 PET/CT显示更高的肿瘤摄取和更好的肿瘤检出能力,尤其在低危和中危前列腺癌患者中,提示[68Ga]Ga-P16-093可能作为前列腺癌检测的替代显像剂。

研究设计与样本

  • 前瞻性头对头比较研究,纳入50例未经治疗、经穿刺活检组织学确诊的原发性前列腺癌患者。
  • 每例患者在一周内先后接受[68Ga]Ga-P16-093和[68Ga]Ga-PSMA-11 PET/CT。
  • 除视觉分析外,测量标准化摄取值(SUV)用于半定量比较和相关分析。
  • 试验注册号NCT05324332,注册日期2022年4月12日,为回顾性注册。

主要发现

  • [68Ga]Ga-P16-093 PET/CT检出阳性肿瘤202个 vs [68Ga]Ga-PSMA-11 PET/CT检出190个(P=0.002)。
  • 前列腺内病灶检出:48个 vs 41个(P=0.016);转移性病灶检出:154个 vs 149个(P=0.125)。
  • 低危和中危前列腺癌患者前列腺内病灶检出:21/23 vs 15/23(P=0.031)。
  • 大多数匹配肿瘤的SUVmax:[68Ga]Ga-P16-093为13.7±10.2 vs [68Ga]Ga-PSMA-11为11.4±8.3(P<0.001)。
  • 正常器官SUVmean:肾脏20.1±6.1 vs 29.3±9.1(P<0.001),膀胱6.5±7.1 vs 20.9±17.4(P<0.001),腮腺8.7±2.6 vs 7.6±2.1(P<0.001),肝脏7.0±1.9 vs 3.7±1.3(P<0.001),脾脏8.2±3.0 vs 5.2±2.2(P<0.001)。

临床怎么用

  • 作者认为[68Ga]Ga-P16-093可能作为前列腺癌检测的替代显像剂。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We aimed to compare the diagnostic performance and biodistribution of two similar PET agents, [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11, in the same group of primary prostate cancer (PCa) patients. METHODS: Fifty patients with untreated, histologically confirmed PCa by needle biopsy were enrolled. Each patient underwent [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11 PET/CT within a week. In addition to visual analysis, the standardized uptake value (SUV) was measured for semiquantitative comparison and correlation analysis. RESULTS: [68Ga]Ga-P16-093 PET/CT detected more positive tumors than [68Ga]Ga-PSMA-11 PET/CT (202 vs. 190, P = 0.002), both for intraprostatic lesions (48 vs. 41, P = 0.016) and metastatic lesions (154 vs. 149, P = 0.125), especially for intraprostatic lesions in low- and intermediate-risk PCa patients (21/23 vs. 15/23, P = 0.031). Furthermore, [68Ga]Ga-P16-093 PET/CT exhibited a significantly higher SUVmax for most matched tumors (13.7 ± 10.2 vs. 11.4 ± 8.3, P < 0.001). For normal organs, [68Ga]Ga-P16-093 PET/CT showed significantly lower activity in the kidney (SUVmean: 20.1 ± 6.1 vs. 29.3 ± 9.1, P < 0.001) and urinary bladder (SUVmean: 6.5 ± 7.1 vs. 20.9 ± 17.4, P < 0.001), but displayed a higher uptake in the parotid gland (SUVmean: 8.7 ± 2.6 vs. 7.6 ± 2.1, P < 0.001), liver (SUVmean: 7.0 ± 1.9 vs. 3.7 ± 1.3, P < 0.001), and spleen (SUVmean: 8.2 ± 3.0 vs. 5.2 ± 2.2, P < 0.001) than [68Ga]Ga-PSMA-11 PET/CT. CONCLUSION: [68Ga]Ga-P16-093 PET/CT demonstrated higher tumor uptake and better tumor detectability than [68Ga]Ga-PSMA-11 PET/CT, especially in low- and intermediate-risk PCa patients, which indicated that [68Ga]Ga-P16-093 may serve as an alternative agent for detection of PCa. TRIAL REGISTRATION: 68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients (NCT05324332, Registered 12 April 2022, retrospectively registered). URL OF REGISTRY: https://clinicaltrials.gov/ct2/show/NCT05324332 .

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wang G, Li L, Zhu M, et al. A prospective head-to-head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer. Eur J Nucl Med Mol Imaging. 2023. PMID: 37233785. doi:10.1007/s00259-023-06283-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。